






Networks 1,2,3 Merged2



A




D




B


Supplementary Fig S2















C











E










I

Clinicopathological features of TCGA prostate cancer patients for study

Characteristics	Total Cases N	Tumor Adjacent Normal N(%)	Hormone Therapy N(%)	P-value
Characteristics				
Male	498	52 (10.44%)	70 (14.05%)	
Female	0	0	0	
Age (years)				
Mean ± SD	61.02±6.81	60.28±7.24	61.36±5.34	
Range	41-78	43-72	51-75	
Follow up days				
Mean ± SD	700.95±693.376	435.03±491.46	1255.58±662.01	
Range	1-4604	1-1925	62-3247	
Gleason_score				
Mean ± SD	7.61±1.008	7.11±0.669	8.73±0.623	
Range	6-10	6-9	7-10	
Distant Metastasis				0.207
M0 (No)	455 (91.36%)	48 (92.30%)	64 (91.42%)	
M1 (Yes)	4 (0.80%)	0	2 (2.85%)	
Lymph node metastasis				<<0.01
N0	345 (69.227%)	46 (88.46%)	33 (47.14%)	
N1	79 (15.86%)	1 (1.92%)	33 (47.14%)	
Depth of tumor invasion				<<0.01
T1+T2	187 (35.55%)	29 (55.76%)	2 (2.85%)	
T3+T4	303 (60.84%)	23 (44.23%)	31 (44.28%)	

Abbreviations: SD, standard deviation; N, number; P-values were calculated by Pearson's chi-squared test.



Supplementary Figure legends:

Figure S1. Analysis of correlation between AR and β -catenin in PCa.

Figure S2. The Wnt/ β -catenin pathway is activated in cell lines and human specimens.

Figure S3. Treatment with ICG001 overcomes enzalutamide resistance in PCa.

Figure S4. Activation of the Wnt/ β -catenin pathway contributes to enzalutamide resistance.

Figure S5. Different gene signature in human PCa specimens and correlation between β -catenin and survival probability.